138 related articles for article (PubMed ID: 15113058)
1. Advantages and differences of Resovist towards Gadolinium contrast in MRI with focus on metastatic liver lesions.
Reimer P; Balzer T
Eur Radiol; 2004 Jan; 14 Suppl 1():C4. PubMed ID: 15113058
[No Abstract] [Full Text] [Related]
2. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced MRI of focal liver lesions: differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient.
Hammerstingl R; Vogl TJ; Schwarz W; Kümmel S; Balzer T; Neuhaus P; Felix R
Acad Radiol; 1998 Apr; 5 Suppl 1():S75-9; discussion S93-4. PubMed ID: 9561049
[No Abstract] [Full Text] [Related]
4. Resovist for imaging of hepatocellular carcinoma in the cirrhotic liver.
Weishaupt D; Willmann JK; Lutz AM; Marincek B
Eur Radiol; 2004 Jan; 14 Suppl 1():C5-6. PubMed ID: 15113059
[No Abstract] [Full Text] [Related]
5. Experience with Resovist in gastroenterologic radiology and intervention.
Vogl TJ; Schwarz W; Marquart F; Parmentier S; Götz B; Thalhammer A; Hammerstingl R
Eur Radiol; 2004 Jan; 14 Suppl 1():C7-9. PubMed ID: 15113060
[No Abstract] [Full Text] [Related]
6. Preoperative patient work-up: Resovist-enhanced MRI vs. multislice CT--preliminary results of an ongoing study.
Heinz-Peer G
Eur Radiol; 2004 Jan; 14 Suppl 1():C11-2. PubMed ID: 15113062
[No Abstract] [Full Text] [Related]
7. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.
Vogl TJ; Schwarz W; Blume S; Pietsch M; Shamsi K; Franz M; Lobeck H; Balzer T; del Tredici K; Neuhaus P; Felix R; Hammerstingl RM
Eur Radiol; 2003 Feb; 13(2):262-72. PubMed ID: 12598989
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of Resovist-enhanced MRI: results of an Italian multicenter trial.
Lencioni R; Bartolozzi C;
Eur Radiol; 2004 Jan; 14 Suppl 1():C10. PubMed ID: 15113061
[No Abstract] [Full Text] [Related]
9. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
Mintorovitch J; Shamsi K
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of the contrast behavior of typical focal hepatic lesions before and after the administration of Gd-DTPA and superparamagnetic iron oxide particles.
Helmberger T; Holzknecht N; Reiser M
Acad Radiol; 2002 Aug; 9 Suppl 2():S468-72. PubMed ID: 12188311
[No Abstract] [Full Text] [Related]
11. [MR contrast agent: resovist (SH U 555A)].
Nakajima H; Ichikawa T
Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
[No Abstract] [Full Text] [Related]
12. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
Kim YK; Kwak HS; Han YM; Kim CS
J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
[TBL] [Abstract][Full Text] [Related]
13. [T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): results of a phantom study as well as 25 patients].
Müller M; Reimer P; Wiedermann D; Allkemper T; Marx C; Tombach B; Rummeny EJ; Shamsi K; Balzer T; Peters PE
Rofo; 1998 Mar; 168(3):228-36. PubMed ID: 9551108
[TBL] [Abstract][Full Text] [Related]
14. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
[TBL] [Abstract][Full Text] [Related]
15. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)].
Reimer P; Tombach B; Daldrup H; Hesse T; Sander G; Balzer T; Shamsi K; Berns T; Rummeny EJ; Peters PE
Radiologe; 1996 Feb; 36(2):124-33. PubMed ID: 8867429
[TBL] [Abstract][Full Text] [Related]
16. [Detection of liver lesions: magnetic resonance tomography using superparamagnetic iron particles (AMI-25, endorem) as a contrast medium in comparison with ultrasound diagnosis, computerized tomography and CT portography].
Pleger B; Beyer HK; Laufer U
Rontgenpraxis; 2001; 53(6):245-9. PubMed ID: 11402872
[No Abstract] [Full Text] [Related]
17. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
[TBL] [Abstract][Full Text] [Related]
18. Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging.
Takahama K; Amano Y; Hayashi H; Ishihara M; Kumazaki T
Abdom Imaging; 2003; 28(4):525-30. PubMed ID: 14580096
[TBL] [Abstract][Full Text] [Related]
19. Health economic evaluation of liver MRI in colorectal cancer patients.
Helmberger T; Annemans L; Warie H; Müller U
Eur Radiol; 2004 Jan; 14 Suppl 1():C13. PubMed ID: 15113063
[No Abstract] [Full Text] [Related]
20. SPIO-MRI in the detection of hepatocellular carcinoma.
Araki T
J Gastroenterol; 2000; 35(11):874-6. PubMed ID: 11085500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
